BACKGROUND: Cigarette smoking is the leading preventable cause of death. Unfortunately, the majority of smokers who attempt to quit smoking relapse within weeks. Abnormal dorsal anterior cingulate cortex (dACC) function may contribute to tobacco smoking relapse vulnerability. Growing evidence suggests that glutamate neurotransmission is involved in mediating nicotine dependence. We hypothesized that prior to a cessation attempt, dACC glutamate levels would be lower in relapse vulnerable smokers. METHODS: Proton magnetic resonance spectra (MRS) were obtained from dACC and a control region, the parieto-occipital cortex (POC), using two-dimensional J-resolved MRS at 4T and analyzed using LCModel. Nine nicotine-dependent women were scanned prior to making a quit attempt. Subjects then were divided into two groups; those able to maintain subsequent abstinence aided by nicotine replacement therapy (NRT) and those who slipped while on NRT (smoked any part of a cigarette after attaining at least 24h of abstinence). RESULTS: Slip subjects exhibited significantly reduced dACC MRS glutamate (Glu/Cr) levels (p<0.03) compared to abstinent subjects. This effect was not observed in the POC control region. CONCLUSIONS: Our preliminary findings suggest that dACC Glu levels as measured with MRS may help identify and/or be a biomarker for relapse vulnerable smokers. Future research following up on these findings may help clarify the role of dACC Glu in smoking dependence that may lead to new treatment strategies.
BACKGROUND: Cigarette smoking is the leading preventable cause of death. Unfortunately, the majority of smokers who attempt to quit smoking relapse within weeks. Abnormal dorsal anterior cingulate cortex (dACC) function may contribute to tobacco smoking relapse vulnerability. Growing evidence suggests that glutamate neurotransmission is involved in mediating nicotine dependence. We hypothesized that prior to a cessation attempt, dACCglutamate levels would be lower in relapse vulnerable smokers. METHODS: Proton magnetic resonance spectra (MRS) were obtained from dACC and a control region, the parieto-occipital cortex (POC), using two-dimensional J-resolved MRS at 4T and analyzed using LCModel. Nine nicotine-dependent women were scanned prior to making a quit attempt. Subjects then were divided into two groups; those able to maintain subsequent abstinence aided by nicotine replacement therapy (NRT) and those who slipped while on NRT (smoked any part of a cigarette after attaining at least 24h of abstinence). RESULTS: Slip subjects exhibited significantly reduced dACCMRSglutamate (Glu/Cr) levels (p<0.03) compared to abstinent subjects. This effect was not observed in the POC control region. CONCLUSIONS: Our preliminary findings suggest that dACCGlu levels as measured with MRS may help identify and/or be a biomarker for relapse vulnerable smokers. Future research following up on these findings may help clarify the role of dACCGlu in smoking dependence that may lead to new treatment strategies.
Authors: Teresa R Franklin; Kimberly Napier; Ronald Ehrman; Peter Gariti; Charles P O'Brien; Anna Rose Childress Journal: Nicotine Tob Res Date: 2004-02 Impact factor: 4.244
Authors: John G Kerns; Jonathan D Cohen; Angus W MacDonald; Raymond Y Cho; V Andrew Stenger; Cameron S Carter Journal: Science Date: 2004-02-13 Impact factor: 47.728
Authors: Carolyn M Mazure; Benjamin Toll; Sherry A McKee; Ran Wu; Stephanie S O'Malley Journal: Drug Alcohol Depend Date: 2010-09-15 Impact factor: 4.492
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Allison S Brandt; Paul G Unschuld; Subechhya Pradhan; Issel Anne L Lim; Gregory Churchill; Ashley D Harris; Jun Hua; Peter B Barker; Christopher A Ross; Peter C M van Zijl; Richard A E Edden; Russell L Margolis Journal: Schizophr Res Date: 2016-02-28 Impact factor: 4.939
Authors: Linda Chang; Christine C Cloak; Caroline S Jiang; Aaron Hoo; Antonette B Hernandez; Thomas M Ernst Journal: J Neuroimmune Pharmacol Date: 2011-09-13 Impact factor: 4.147
Authors: Muriah D Wheelock; Meredith A Reid; Harrison To; David M White; Karen L Cropsey; Adrienne C Lahti Journal: Front Pharmacol Date: 2014-07-08 Impact factor: 5.810